Virtual Clinical Trials Market Size, Share, and Analysis, By Study Type (Interventional, Observational, Expanded Access), By Phase (Phase I, Phase II, Phase III, Phase IV), By Indication (CNS, Autoimmune/Inflammation, Cardiovascular Disease, Metabolic/Endocrinology, Infectious Disease, Oncology, Genitourinary, Ophthalmology, Others) and Regional Forecasts, 2022-2032

January 2024 | 430 pages | ID: VB2F165FE5FBEN
Fatpos Global

Abstracts

Virtual Clinical Trials Market Size, Share, and Analysis, By Study Type (Interventional, Observational, Expanded Access), By Phase (Phase I, Phase II, Phase III, Phase IV), By Indication (CNS, Autoimmune/Inflammation, Cardiovascular Disease, Metabolic/Endocrinology, Infectious Disease, Oncology, Genitourinary, Ophthalmology, Others) and Regional Forecasts, 2022-2032

PRODUCT OVERVIEW

Virtual Clinical Trials Market size was USD 7.73 billion in 2021 and projected to grow from USD 8.7 billion in 2023 to USD 15.3 billion by 2032, exhibiting a CAGR of 6.4% during the forecast period.

Virtual Clinical Trials are commonly referred as ‘the decentralized trials’. They are a comparatively fresh addition to the health research domain. They control digital technologies and tools to gather information from members distantly or remotely, in their working or natural living surroundings. The key advantages of virtual clinical trials comprise cost efficiencies, enhanced patient engagement, better data capture and authorized research groups.

MARKET HIGHLIGHTS

Virtual Clinical Trials Market is expected to reach USD 15.3 billion, growing at a CAGR of 6.4% during the forecast period owing to the growing penetration of the adoption of virtual clinical trials and rising number of different illnesses and chronic diseases worldwide. Moreover, the rising adoption of improved and modern technologies in clinical research activities is expected to propel the Virtual Clinical Trials Market.

Virtual Clinical Trials Market Segments:

• Study Type
• Interventional
• Observational
• Expanded Access
• Phase
• Phase I
• Phase II
• Phase III
• Phase IV
• Indication
• CNS
• Autoimmune/Inflammation
• Cardiovascular Disease
• Metabolic/Endocrinology
• Infectious Disease
• Oncology
• Genitourinary
• Ophthalmology
• Others

MARKET DYNAMICS

Growth Drivers

Mounting R&D Activities and Supportive Government Initiatives are Expected to Boost the Market Growth

Benefits and Convenience of Virtual Methods to the Patients are Expected to Boost the Market Growth

Restraint

Stringent Regulations and Data Privacy of Patients May Restrain the Market Growth

Key Players

• Accenture
• Oracle Corporation
• J&J Innovative Medicine
• IQVIA Holdings Inc.
• Labcorp Drug Development
• ICON Plc
• Dassault Systemes SE
• Parexel International Corporation
• Clario
• Medpace Holdings Inc.
• Medidata
• Signant Health
• Medable Inc.
• Clinical Ink
• Croprime
• Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)

Global Laboratory Temperature Control Units Market is further segmented by region into:

• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAG.R – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 3-month post-sales analyst support.

Contents

1. EXECUTIVE SUMMARY

1.1.Regional Market Share
1.2. Business Trends
1.3. Virtual Clinical Trials Market: COVID-19 Outbreak
1.4.Regional Trends
1.5. Segmentation Snapshot

2. RESEARCH METHODOLOGY

2.1. Research Objective
2.2.Research Approach
2.3.Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
  2.5.1.Paid Sources
  2.5.2. Public Sources
2.6.Market Size Estimation and Data Triangulation

3. MARKET CHARACTERISTICS

3.1. Market Definition
3.2.Virtual Clinical Trials Market: COVID-19 Impact
3.3.Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data

4. VIRTUAL CLINICAL TRIALS MARKET – INDUSTRY INSIGHTS

4.1.Industry Segmentation
4.2. COVID-19 overview on world economy
4.3. Industry ecosystem Channel analysis
4.4. Innovation & Sustainability

5. MACROECONOMIC INDICATORS


6. RECENT DEVELOPMENTS


7.MARKET DYNAMICS

7.1. Introduction
7.2.Growth Drivers
7.3.Market Opportunities
7.4. Market Restraints
7.5.Market Trends

8. MARKET ANALYSIS

8.1. Porters Five Forces
8.2. PEST Analysis
  8.2.1. Political
  8.2.2.Economic
  8.2.3.Social
  8.2.4.Technological

9. VIRTUAL CLINICAL TRIALS MARKET

9.1. Overview
9.2.Historical Analysis (2016-2021)
  9.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast

10. VIRTUAL CLINICAL TRIALS MARKET SIZE & FORECAST 2022A-2032F

10.1.Overview
10.2. Key Findings
10.3. Market Segmentation
  10.3.1. By Study Type
    10.3.1.1.Interventional
      10.3.1.1.1.By Value (USD Million) 2022-2032F
      10.3.1.1.2. Market Share (%) 2022-2032F
      10.3.1.1.3. Y-o-Y Growth (%) 2022-2032F
    10.3.1.2. Observational
      10.3.1.2.1. By Value (USD Million) 2022-2032F
      10.3.1.2.2.Market Share (%) 2022-2032F
      10.3.1.2.3.Y-o-Y Growth (%) 2022-2032F
    10.3.1.3. Expanded Access
      10.3.1.3.1. By Value (USD Million) 2022-2032F
      10.3.1.3.2.Market Share (%) 2022-2032F
      10.3.1.3.3.Y-o-Y Growth (%) 2022-2032F
  10.3.2.By Application
    10.3.2.1. Phase I
      10.3.2.1.1. By Value (USD Million) 2022-2032F
      10.3.2.1.2.Market Share (%) 2022-2032F
      10.3.2.1.3.Y-o-Y Growth (%) 2022-2032F
    10.3.2.2.Phase II
      10.3.2.2.1.By Value (USD Million) 2022-2032F
      10.3.2.2.2. Market Share (%) 2022-2032F
      10.3.2.2.3. Y-o-Y Growth (%) 2022-2032F
    10.3.2.3.Phase III
      10.3.2.3.1.By Value (USD Million) 2022-2032F
      10.3.2.3.2. Market Share (%) 2022-2032F
      10.3.2.3.3.Y-o-Y Growth (%) 2022-2032F
    10.3.2.4.Phase IV
      10.3.2.4.1. By Value (USD Million) 2022-2032F
      10.3.2.4.2.Market Share (%) 2022-2032F
      10.3.2.4.3.Y-o-Y Growth (%) 2022-2032F
  10.3.3.By Indication
    10.3.3.1. CNS
      10.3.3.1.1. By Value (USD Million) 2022-2032F
      10.3.3.1.2.Market Share (%) 2022-2032F
      10.3.3.1.3.Y-o-Y Growth (%) 2022-2032F
    10.3.3.2.Autoimmune/Inflammation
      10.3.3.2.1.By Value (USD Million) 2022-2032F
      10.3.3.2.2. Market Share (%) 2022-2032F
      10.3.3.2.3.Y-o-Y Growth (%) 2022-2032F
    10.3.3.3.Cardiovascular Disease
      10.3.3.3.1.By Value (USD Million) 2022-2032F
      10.3.3.3.2.Market Share (%) 2022-2032F
      10.3.3.3.3.Y-o-Y Growth (%) 2022-2032F
    10.3.3.4.Metabolic/Endocrinology
      10.3.3.4.1. By Value (USD Million) 2022-2032F
      10.3.3.4.2.Market Share (%) 2022-2032F
      10.3.3.4.3.Y-o-Y Growth (%) 2022-2032F
    10.3.3.5.Infectious Disease
      10.3.3.5.1. By Value (USD Million) 2022-2032F
      10.3.3.5.2.Market Share (%) 2022-2032F
      10.3.3.5.3.Y-o-Y Growth (%) 2022-2032F
    10.3.3.6.Oncology
      10.3.3.6.1.By Value (USD Million) 2022-2032F
      10.3.3.6.2. Market Share (%) 2022-2032F
      10.3.3.6.3. Y-o-Y Growth (%) 2022-2032F
    10.3.3.7.Genitourinary
      10.3.3.7.1.By Value (USD Million) 2022-2032F
      10.3.3.7.2. Market Share (%) 2022-2032F
      10.3.3.7.3. Y-o-Y Growth (%) 2022-2032F
    10.3.3.8.Ophthalmology
      10.3.3.8.1. By Value (USD Million) 2022-2032F
      10.3.3.8.2.Market Share (%) 2022-2032F
      10.3.3.8.3.Y-o-Y Growth (%) 2022-2032F
    10.3.3.9.Others
      10.3.3.9.1.By Value (USD Million) 2022-2032F
      10.3.3.9.2. Market Share (%) 2022-2032F
      10.3.3.9.3. Y-o-Y Growth (%) 2022-2032F

11.NORTH AMERICA VIRTUAL CLINICAL TRIALS MARKET SIZE & FORECAST 2022A-2032F

11.1.Overview
11.2. Key Findings
11.3. Market Segmentation
  11.3.1.By Study Type
  11.3.2. By Phase
  11.3.3. By Indication
11.4.Country
  11.4.1. United States
  11.4.2.Canada

12. EUROPE VIRTUAL CLINICAL TRIALS MARKET SIZE & FORECAST 2022A-2032F

12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
  12.3.1. By Study Type
  12.3.2.By Phase
  12.3.3.By Indication
12.4. Country
  12.4.1.Germany
  12.4.2. United Kingdom
  12.4.3. France
  12.4.4. Italy
  12.4.5. Spain
  12.4.6. Russia
  12.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)

13. ASIA VIRTUAL CLINICAL TRIALS MARKET SIZE & FORECAST 2022A-2032F

13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
  13.3.1. By Study Type
  13.3.2.By Phase
  13.3.3.By Indication
13.4. Country
  13.4.1.India
  13.4.2. China
  13.4.3. South Korea
  13.4.4. Japan
  13.4.5. Rest of APAC

14. MIDDLE EAST AND AFRICA VIRTUAL CLINICAL TRIALS MARKET SIZE & FORECAST 2022A-2032F

14.1.Overview
14.2. Key Findings
14.3. Market Segmentation
  14.3.1. By Study Type
  14.3.2.By Phase
  14.3.3.By Indication
14.4. Country
  14.4.1.Israel
  14.4.2. GCC
  14.4.3. North Africa
  14.4.4. South Africa
  14.4.5. Rest of Middle East and Africa

15. LATIN AMERICA VIRTUAL CLINICAL TRIALS MARKET SIZE & FORECAST 2022A-2032F

15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
  15.3.1. By Study Type
  15.3.2.By Phase
  15.3.3.By Indication
15.4. Country
  15.4.1.Mexico
  15.4.2. Brazil
  15.4.3. Rest of Latin America

16. COMPETITIVE LANDSCAPE

16.1. Company market share, 2021
16.2. Key player overview
16.3. Key stakeholders

17. COMPANY PROFILES

17.1.Accenture
  17.1.1.Company Overview
  17.1.2. Financial Overview
  17.1.3. Key Product; Analysis
  17.1.4.Company Assessment
    17.1.4.1.Product Portfolio
    17.1.4.2. Key Clients
    17.1.4.3. Market Share
    17.1.4.4. Recent News & Development (Last 3 Yrs.)
    17.1.4.5. Executive Team
17.2. Oracle Corporation
17.3. J&J Innovative Medicine
17.4. IQVIA Holdings Inc.
17.5. Labcorp Drug Development
17.6. ICON Plc
17.7. Dassault Systemes SE
17.8. Parexel International Corporation
17.9. Clario
17.10. Medpace Holdings Inc.
17.11.Medidata
17.12. Signant Health
17.13. Medable Inc.
17.14. Clinical Ink
17.15. Croprime
17.16. Other Prominent Players

18. APPENDIX


19. CONSULTANT RECOMMENDATION